Health for all: How can we contribute to inclusive access?
What drives us to improve the health of humans and animals worldwide
Search
Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.
SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry
Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being
Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
Do you take periodontal disease in dogs seriously? We do!
Periodontal Disease? Brushing teeth is vital to prevent doggy breath, but not enough to ensure animal health and well-being
European Election: Europe needs our vote
This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
The Unwearable Collection™: Fashion Inspired by GPP
An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
FreVAX smartphone application piglet vaccination
New FreVAX™ smartphone application brings piglet vaccination to another level
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
A tool to aid in the prevention of African swine fever
ASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever introduction risk level.
Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
Boehringer Ingelheim leader in hatchery vaccination
Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
Small Cell Lung Cancer
Discover more about small cell lung cancer, including its symptoms and treatment options.